Effect of irinotecan on urinary Δ9- tetrahydrocannabinol elimination in Wistar rats (CROSBI ID 677011)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Brčić Karačonji, Irena ; Miljanić, Alena ; Jurič, Andreja ; Brajenović, Nataša ; Micek, Vedran ; Neuberg, Marijana ; Kozina, Goran ; Lucić Vrdoljak, Ana ; Mikolić, Anja
engleski
Effect of irinotecan on urinary Δ9- tetrahydrocannabinol elimination in Wistar rats
Background: Due to growing public interest in the antitumor potential of Δ9- tetrahydrocannabinol (THC) and its possible role as an agent for alleviating side-effects of chemotherapy with irinotecan (IRI), some oncology patients have begun to reach for highly concentrated THC preparations. Since IRI, THC and their metabolites are subjected to glucuronic acid conjugation via the same enzyme (UGT1A1), co-administered THC could reduce IRI metabolism and clearance of its metabolites (particularly SN-38), leading to enhanced toxicity. Objective: The aim of the study was to compare the urinary elimination of free (non- conjugated) THC and its metabolites [11-hydroxy- Δ9-THC (THC- OH) and 11-nor-9-carboxy-Δ9-THC (THC-COOH)] in IRI+THC treated rats with rats treated only with THC. Methods: Male Wistar rats (N = 5 per group) were administered a combination of a single dose of IRI (100 mg/kg b.w, i.p.) and THC (7 mg/kg b.w., p.o.) or THC only. Urine samples were collected during the first 24 h after the treatment. THC, THC-OH and THC-COOH concentrations were determined by gas chromatography-mass spectrometry. Results: Enhanced urinary THC-OH and THC-COOH excretion was noted in rats administered combined treatment compared to single THC treatment. Conclusion: Increased non-conjugated THC metabolite urinary concentrations in combined treatment might point to the competition of THC and IRI for the same enzyme in phase II metabolism. Further studies are needed to elucidate the increase of the free fraction of THC metabolites in the concomitant use of IRI and THC.
Tetrahydrocannabinol ; irinotecan ; urinary elimination ; GC-MS ; rat
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
3-4.
2019.
nije evidentirano
objavljeno
10.1159/000500623
Podaci o matičnoj publikaciji
The abstracts of The 2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis2019)
Häuser, Winfried ; Brill, Silviu
Basel: S. Karger AG, Basel
2504-3889
Podaci o skupu
2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis2019)
poster
23.05.2019-24.05.2019
Barcelona, Španjolska